iSYNAPSE: Early signals of the transition from immune quiescence to activation in the liver allograft microenvironment and in the circulation

iSYNAPSE:肝脏同种异体移植物微环境和循环中从免疫静止过渡到激活的早期信号

基本信息

  • 批准号:
    10622220
  • 负责人:
  • 金额:
    $ 27.07万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-08-02 至 2024-07-31
  • 项目状态:
    已结题

项目摘要

iSYNAPSE Summary Children with liver transplants with excellent graft function according to clinical, biochemical, and histological criteria enjoy a harmonious equilibrium between the host immune system and the allograft. Reducing immunosuppression is challenge that, for some but not all, precipitates alloimmune activation that can result in graft injury. Previously, we have shown that objective quantification of inflammatory load using next generation pathology techniques can meaningfully differentiate allografts that appear normal by standard histological evaluation. The density of various inflammatory cells essentially maps allografts onto an alloreactivity spectrum that extends from quiescent to activated. Among inflammatory metrics, the density of immunologic synapses, defined as a lymphocyte proximal to and interacting with an antigen-presenting cell based on positional, morphometric, and molecular parameters, was the best predictor of those who could withstand the challenge of immunosuppression dose reduction to complete cessation. These data suggest that, within an apparently quiescent allograft, the intrahepatic microenvironment, comprised of immune cells and their cell-to-cell interactions, determines the likelihood of maintaining quiescence or succumbing to activation when IS is reduced. Our primary hypothesis is that the number and nature of interactions between intrahepatic immune cells at quiescence constitutes the basis of liver allograft immunogenicity and is the key determinant of outcome, when quiescence is challenged. To test this hypothesis, iSYNAPSE proposes the following specific aims: 1) Conduct a multicenter, single-arm trial for stable children with healthy liver allografts on calcineurin inhibitor monotherapy. Immunosuppression will be reduced by 50%, from twice to once daily dosing. This intervention offers direct prospect of benefit by reducing medication exposure and simplifying administration. 2) Determine how intrahepatic immune cell networks regulate liver allograft immunogenicity at baseline and following immunosuppression reduction. Using next generation pathology and single cell transcriptomics, we will characterize the phenotype and the transcriptome of the lymphocytes and the antigen-presenting cells participating in immunological synapses. The iterative analyses of these two data streams will fully inventory the immune cell subsets that comprise the liver microenvironment and elucidate the impact of cell-to-cell interactions on the maintenance or loss of quiescence when challenged. 3) Ascertain whether the nature of intrahepatic cell-to-cell interactions predict changes in donor-specific humoral and cellular responses in the circulation. Liver transplantation provides a unique context to safely study the host and graft respond when the equilibrium achieved by immunosuppression is challenged. Understanding these basic mechanisms of how allograft quiescence is maintained or lost when stressed is essential to navigate the treacherous balance between over- and under-immunosuppression that translate into suboptimal outcomes for either the patient or the graft.
iSYNAPSE总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Sandy Feng其他文献

Sandy Feng的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Sandy Feng', 18)}}的其他基金

Polyclonal Tregs to Promote Tolerance in Pediatric Liver Transplant Recipients
多克隆 Tregs 可促进儿童肝移植受者的耐受性
  • 批准号:
    8610243
  • 财政年份:
    2013
  • 资助金额:
    $ 27.07万
  • 项目类别:
Polyclonal Tregs to Promote Tolerance in Pediatric Liver Transplant Recipients
多克隆 Tregs 可促进儿童肝移植受者的耐受性
  • 批准号:
    9005804
  • 财政年份:
    2013
  • 资助金额:
    $ 27.07万
  • 项目类别:
Polyclonal Tregs to Promote Tolerance in Pediatric Liver Transplant Recipients
多克隆 Tregs 可促进儿童肝移植受者的耐受性
  • 批准号:
    8466591
  • 财政年份:
    2013
  • 资助金额:
    $ 27.07万
  • 项目类别:
Immunosuppression Withdrawal for Stable Pediatric Liver Transplant Recipients
稳定儿童肝移植受者的免疫抑制撤药
  • 批准号:
    8332618
  • 财政年份:
    2012
  • 资助金额:
    $ 27.07万
  • 项目类别:
Immunosuppression Withdrawal for Stable Pediatric Liver Transplant Recipients
稳定儿童肝移植受者的免疫抑制撤药
  • 批准号:
    8704875
  • 财政年份:
    2012
  • 资助金额:
    $ 27.07万
  • 项目类别:
Immunosuppression Withdrawal for Stable Pediatric Liver Transplant Recipients
稳定儿童肝移植受者的免疫抑制撤药
  • 批准号:
    8515928
  • 财政年份:
    2012
  • 资助金额:
    $ 27.07万
  • 项目类别:
Immunosuppression Withdrawal for Stable Pediatric Liver Transplant Recipients
稳定儿童肝移植受者的免疫抑制撤药
  • 批准号:
    8054698
  • 财政年份:
    2010
  • 资助金额:
    $ 27.07万
  • 项目类别:
Immunosuppression Withdrawal for Stable Pediatric Liver Transplant Recipients
稳定儿童肝移植受者的免疫抑制撤药
  • 批准号:
    8334913
  • 财政年份:
    2009
  • 资助金额:
    $ 27.07万
  • 项目类别:
Immunosuppression Withdrawal for Stable Pediatric Liver Transplant Recipients
稳定儿童肝移植受者的免疫抑制撤药
  • 批准号:
    7943019
  • 财政年份:
    2009
  • 资助金额:
    $ 27.07万
  • 项目类别:
Immunosuppression Withdrawal for Stable Pediatric Liver Transplant Recipients
稳定儿童肝移植受者的免疫抑制撤药
  • 批准号:
    7738992
  • 财政年份:
    2009
  • 资助金额:
    $ 27.07万
  • 项目类别:

相似海外基金

Establishment of novel osteochondral allografting combined with growth factor- collagen-binding domain fusion technology
新型同种异体骨软骨移植联合生长因子-胶原蛋白结合域融合技术的建立
  • 批准号:
    26462277
  • 财政年份:
    2014
  • 资助金额:
    $ 27.07万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Translating PTH Therapy as an Adjuvant for Structural Allografting
将 PTH 疗法转化为结构性同种异体移植的佐剂
  • 批准号:
    8344380
  • 财政年份:
    2012
  • 资助金额:
    $ 27.07万
  • 项目类别:
Allografting for Lukemia
白血病同种异体移植
  • 批准号:
    8260361
  • 财政年份:
    2011
  • 资助金额:
    $ 27.07万
  • 项目类别:
Composite Allografting for Promoting Survival of Corneal Transplants
复合同种异体移植促进角膜移植的存活
  • 批准号:
    7878675
  • 财政年份:
    2009
  • 资助金额:
    $ 27.07万
  • 项目类别:
Composite Allografting for Promoting Survival of Corneal Transplants
复合同种异体移植促进角膜移植的存活
  • 批准号:
    7677758
  • 财政年份:
    2009
  • 资助金额:
    $ 27.07万
  • 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
  • 批准号:
    7466112
  • 财政年份:
    2008
  • 资助金额:
    $ 27.07万
  • 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
  • 批准号:
    8010394
  • 财政年份:
    2008
  • 资助金额:
    $ 27.07万
  • 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
  • 批准号:
    8208131
  • 财政年份:
    2008
  • 资助金额:
    $ 27.07万
  • 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
  • 批准号:
    7575273
  • 财政年份:
    2008
  • 资助金额:
    $ 27.07万
  • 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
  • 批准号:
    7765518
  • 财政年份:
    2008
  • 资助金额:
    $ 27.07万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了